Apalutamide Safe and Effective in Treatment of High-Risk Nonmetastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-Risk Nonmetastatic Castration-Resistant Prostate Cancer Cohort
Eur Urol 2016 Dec 01;70(6)963-970, MR Smith, ES Antonarakis, CJ Ryan, WR Berry, ND Shore, G Liu, JJ Alumkal, CS Higano, E Chow Maneval, R Bandekar, CJ de Boer, MK Yu, DE RathkopfFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.